Michael Bookman
Medical Oncology · Tucson, AZNPI 1972570836
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.7% of the total. Among medical oncology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $1280.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$16K
- Merck$11K
- Genentech, Inc.$7K
- Seagen Inc.$5K
- Myriad Genetic Laboratories, Inc.$3K
- Gilead$2K
- plus $2K from 7 others
Across 404 payments — averaging $11,710 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.7M
- Tesaro, Inc.$984K
- Genentech, Inc.$780K
- GSK$124K
- Eli Lilly$61K
- AstraZeneca$41K
- plus $16K from 4 others
What the payments were for
- Consulting fees$26,44057%
- Speaking & faculty fees$15,52534%
- Grants$1,4633%
- Travel & lodging$1,5703%
- Food & beverage$1,0322%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15,525 |
| Merck | 10 | $10,777 |
| Genentech, Inc. | 2 | $7,260 |
| Seagen Inc. | 7 | $5,186 |
| Myriad Genetic Laboratories, Inc. | 2 | $3,000 |
| Gilead | 4 | $2,279 |
| AstraZeneca | 2 | $1,463 |
| GSK | 3 | $194 |
| Pharmaand GmbH | 1 | $169 |
| Genentech USA, Inc. | 1 | $85 |
| Karyopharm Therapeutics Inc. | 1 | $79 |
| Tesaro, Inc. | 1 | $61 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Avastin$7,260
- TECENTRIQ$7,260
- myChoice CDx$3,000
- Rubraca$169
How this compares
$46,090 in reported general payments places this provider in the 90th percentile of 59 medical oncology providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 45 | $837,714 |
| IbrancePalbociclib | 36 | $555,472 |
| LynparzaOlaparib | 14 | $126,125 |
| Lorazepam | 20 | $222 |
| Ondansetron Hcl | 19 | $172 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $170 |
| Dexamethasone | 12 | $136 |
| Zolpidem Tartrate ErZolpidem Tartrate | 13 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $194 | $837,71445 claims |
| AstraZenecaLynparza | $1,463 | $126,12514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 59 medical oncology providers in Arizona.
Other medical oncology in Tucson
- Delmer Montoya MotinoTucson$26K
- Gerald HaginTucson$1K
- Aparna NallagangulaTucson$321
- Leona DowneyTucson$50
- Morris FineTucson$35
- Jason SalganickPhoenix$1.6M
- Roopesh KantalaMesa$491K
- Nazish AhmadGlendale$205K
- Daniel von HoffScottsdale$165K
- David KahnSurprise$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.